Journals / Retina-Vitreus / 2013 / Cilt: 21 - Sayı: 4

Outcomes of photodynamic therapy with a half dose of verteporfin in patients with chronic central serous chorioretinopathy

Kronik santral seröz koryoretinopatili olgularda yarım doz verteporfin ile uygulanan fotodinamik tedavi sonuçları

Pages
274–278
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Photodynamic therapy with a half the dose verteporfin was considered as an effective treatment in the patients with chronic CSCR.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the effectiveness and the results of photodynamic therapy (PDT) with half the dose verteporfin in chronic central serous chorioretinopathy (CSCR).
📊
Key Findings & Data:Materials and Methods: Nineteen eyes of 19 patients diagnosed with chronic CSCR were included in the study.
💡
Conclusion & Impact:Conclusion: Photodynamic therapy with a half the dose verteporfin was considered as an effective treatment in the patients with chronic CSCR.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the effectiveness and the results of photodynamic therapy (PDT) with half the dose verteporfin in chronic central serous chorioretinopathy (CSCR). Materials and Methods: Nineteen eyes of 19 patients diagnosed with chronic CSCR were included in the study. The diagnoses were made by fundus fluorescein angiography and optical coherence tomography (OCT). Corrected logMAR visual acuity (VA) and central macular thickness (CMT) were analyzed before and after treatment. The baseline and the sixth month results were compared. Results: The mean age of the patients was 37.4±6.1 and 16 (84.2%) of them were male, 3 (15.8%) of them were female. The mean follow-up time was 7.9±2.2 (6-12) months. After PDT, 15 (78.9%) of cases gained minimum one line increase in VA. In three (15.8%) patients visual acuity remained unchanged and in a patient (5.3%) VA decreased one line. There was a significant reduction (p = 0,001) in the mean CMT values when compared before and after PDT. Subretinal fluid in OCT resolved completely in 17 (89.4%) patients and partially in one (5.3%) patients but it showed an increase only in one patient (5.3%). There was not any complication due to PDT in any patients. Conclusion: Photodynamic therapy with a half the dose verteporfin was considered as an effective treatment in the patients with chronic CSCR.

Özet

Amaç: Kronik santral seröz koryoretinopati (SSKR)’li olgularımızda yarım doz verteporfin ile uygulanan fotodinamik tedavi (FDT)’nin etkinliğini ve sonuçlarını değerlendirmek. Gereç ve Yöntem: Kronik SSKR tanısı konulan 19 hastanın 19 gözü çalışmaya dahil edildi. Tanılar fundus flöresein anjiografi ve optik koherens tomografi (OKT) ile konuldu. Olgular düzeltilmiş logMAR görme keskinliği (GK) ve OKT’deki santral maküla kalınlığı (SMK) yönünden tedavi öncesi ve sonrasındaki 6. ay sonuçları için izleme alındı. Bulgular: Olguların ortalama yaşı 37.4±6.1 olup 16 (%84.2)’sı erkek 3 (%15.8)’i kadındı. Ortalama takip süresi 7.9±2.2 (6-12) aydı. FDT sonrası 15 (%78.9) olgunun GK’nde 1 sıra ve üzerinde artış görüldü. Üç (%15.8) olguda görme keskinliği değişmezken, 1 (%5.3) olguda 1 sıra azaldı. Ortalama SMK FDT öncesi ve sonrası değerler karşılaştırıldığında istatistiksel olarak anlamlı bir azalma gözlendi (p=0.001). OKT’de subretinal sıvının 17 (%89.4) gözde tamamen gerilediği, 1 (%5.3) gözde kısmen gerilediği ve 1 (%5.3) gözde sıvıda artış olduğu görüldü. Hiçbir gözde FDT’ye bağlı bir komplikasyon gelişmedi. Sonuç: Yarım doz verteporfin ile uygulanan FDT kronik SSKR’li olguların tedavisinde etkili bir yöntem olarak değerlendirilmiştir.

🔖

Cite This Article

TÜRKÇÜ, F. M., YÜKSEL, H., ŞAHİN, A., ÇINAR, Y., CINGÜ, K., ŞAHİN, M., YILDIRIM, A., ÇAÇA, İ. (2013). Outcomes of photodynamic therapy with a half dose of verteporfin in patients with chronic central serous chorioretinopathy. Retina-Vitreus, Cilt: 21 - Sayı: 4, 274–278. https://ajindex.com/articles/305051

References (15)

  1. Gass JDM. Pathogenesis of disciform detachment of neuroepi-thelium, idiopathic central serous choroidopathy. Am J Ophthalmol 1967
  2. Guyer DR, Gragoudas ES. Central serous chorioretinopathy. In Albert DM, Jakobiec FA (eds): Principles and practice of ophthalmology. WB Saunders Co. Philadelphia 1994
  3. Hussain D, Gass JD. Idiopathic central serous chorioretinopathy. Indian J Ophthalmol 1998
  4. Castro-Correia J, Countinho MF, Rosas V, et al. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992
  5. Levine R, Brucker A, Robinson F. Long-term follow-up of idio-pathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology 1989
  6. Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003
  7. Ficker L, Vafidis G, White A, et al. Long-term follow-up of pro- 8.Verma L, Sinha R, Venkatesh P, et al. Comparative evalu- spective trial of argon laser photocoagulation in the treatment ation of diode laser versus argon laser photocoagulation in of central serous retinopathy. Br J Ophthalmol 1988
  8. patients with central serous retinopathy: A pilot, randomized controlled trial. BMC Ophthalmol 2004
  9. Taban M, Boyer DS, Thomas EL, et al. Chronic central serous chorioretinopathy: Photodynamic therapy. Am J Ophthalmol 2004
  10. Chan WM, Lai TY, Lai RY, et al. Half-dose verteporfin photo-dynamic therapy for acute central serous chorioretinopathy. Ophthalmology 2008
  11. Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: One-year results of a prospective study. Retina 2008
  12. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: Nonrandomized clinical trial. Am J Ophthalmol 2010
  13. Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minne-sota, 1980-2002. Ophthalmology 2008
  14. Schmidt-Erfurth U, Michels S, Barbazetto I, et al. Photody-namic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002
  15. Schlotzer-Schrehardt U, Viestenz A, Naumann GO, et al. Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp